Coherus rises after launching throat cancer therapy

Coherus Oncology

02/01/2024 15:50

** Shares of Coherus BioSciences  CHRS.O  rise as much as
8.1% to a near 2-month high of $3.6 in morning trade
    ** Drugmaker says it has launched Loqtorzi, its therapy for
a type of throat cancer
    ** Nasopharyngeal carcinoma is an aggressive cancer that
starts in the nasopharynx, the upper part of the throat behind
the nose and near the base of the skull 
    ** Eight of 10 brokerages rate the stock "buy" or higher, 2
"hold"; their median PT is $12 - LSEG
    ** CHRS stock fell 58% in 2023

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))